The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.
about
Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysisCloning and characterization of two promoters for the human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas.Regulation of bone remodeling: impact of novel therapies.Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.Chronic kidney disease: mineral and bone disorder in children.Mechanisms of secondary hyperparathyroidism.Novel treatments for osteoporosis.The calcium-sensing receptor and its interacting proteins.Secondary hyperparathyroidism disease stabilization following calcimimetic therapy.Role of the calcium-sensing receptor in parathyroid gland physiology.The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysisCalcimimetics and the treatment of primary and secondary hyperparathyroidism.The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.The calcium-sensing receptor in normal physiology and pathophysiology: a review.Effects of calcium-sensing receptor on the secretion of parathyroid hormone-related peptide and its impact on humoral hypercalcemia of malignancy.Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs.Defining potential roles of Pb(2+) in neurotoxicity from a calciomics approach.The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion.Cinacalcet: will it play a role in reducing cardiovascular events?Gastric acid, calcium absorption, and their impact on bone health.Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.Animal models of hyperfunctioning parathyroid diseases for drug development.Cinacalcet and Clinical Outcomes in Dialysis.Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.Potential roles for calcium-sensing receptor (CaSR) and transient receptor potential ankyrin-1 (TRPA1) in murine anorectic response to deoxynivalenol (vomitoxin).Cycling with the parathyroidCalcium sensing receptor activation by a calcimimetic suggests a link between cooperativity and intracellular calcium oscillations.Antialbuminuric actions of calcilytics in the remnant kidney.Biphasic response as a mechanism against mutant takeover in tissue homeostasis circuits.Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy.Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis.Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1.Dynamical compensation in physiological circuitsCinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats.Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency.Parathyroid Nodular Hyperplasia and Responsiveness to Drug Therapy in Renal Secondary Hyperparathyroidism: An Open Question.Extracellular Ca(2+)-sensing receptor is a promiscuous divalent cation sensor that responds to lead.Calcium-Sensing Receptor and Transient Receptor Ankyrin-1 Mediate Emesis Induction by Deoxynivalenol (Vomitoxin).
P2860
Q28484646-5F5BE135-10EE-4C0A-937C-E55023351885Q30845693-C1369E7A-EF05-4006-B1E6-F27CA84CADE5Q32029051-9A511900-E246-4FCC-8045-5E37A7D7CC1BQ34362759-B1EEE64C-A629-4CC0-BA63-1F04BA12A9C3Q34402661-BCB04DA7-8DDC-4C53-AB43-36201F866955Q34776998-DF85527F-51DD-41FC-82D3-204B4BE0D759Q35126745-14479DBD-DBAC-43BB-931F-A514A56A5A17Q35459486-6412E83F-D6FA-4E21-A58B-C726DF25B83BQ35573653-A368655A-A197-478C-A70D-A7BFEC075AC1Q35766550-C6072219-F32E-4316-8973-BDF8E14B44C6Q35826159-9AE75016-C609-4C00-9C25-6B02223E31FAQ35915930-681D9E9E-6A05-48FA-A999-EA6E876257F9Q35928870-77AEE302-7BCC-4671-89D0-B7CDC86F78CFQ36033289-F62B4774-77B5-4F14-B666-488757BCD5DBQ36444286-029E1AD1-950F-4D86-8314-21446F5C1ED0Q36632228-3351D4C8-B12A-47C7-A9E1-2974BC5C9451Q37164450-FF49BDA7-B937-4DA3-8E49-78D982F39706Q37391736-C4871382-B9EF-4ECE-86DD-A1DD242A2550Q37993874-9C72D416-E39C-4406-9D0D-49241732F2ACQ38072903-EFCEFF19-55FB-440C-B5B2-170A8D7213A7Q38079128-DAE9ABD9-221B-409F-AFD8-89774DD0DA57Q38089204-2A964766-3130-4C3E-9FEE-EA227BD784F6Q38565049-9C38E5A7-9E21-4D5E-8670-7D2B32E02226Q38610957-5F19787B-B70D-4C16-945E-EF2A45420F8DQ39919265-E3C448C3-BE37-4E1B-B457-2B327A0426DEQ39946590-ED75259C-D378-45CA-B1BE-2A8D563C4B27Q40694310-AC23F56D-5B3D-4BBF-8771-F799BEAA5E1EQ40896471-686EED53-5ECB-421A-A6EA-D23824ED03E8Q41016751-E9435437-D36F-4B63-93EB-8CA725EA9FE6Q41202412-C31677F8-7FBD-4EC9-B452-2D8FB1282972Q41575719-32E0EAA2-3E95-40D8-9079-04DF18772A30Q41781008-0E448F1D-68E5-4720-BA05-00BEF96D4167Q41847762-9251E78E-122C-446F-A373-41CAF1B34900Q42181616-872D0E0C-9ECC-4A1A-A8B2-6C1501611D8DQ42741021-BB0AB7A2-49C6-4E3F-A963-79D3B39E6F72Q46192901-2530D420-68B6-41B1-BC6A-284458CE3734Q46709389-45F824C3-0E59-4E7E-9BC4-476A9D387F9BQ48239717-4A692B6F-58B7-4FDF-8797-7B0433E8FF66Q50106745-3C7FFB82-DE53-4F64-94A3-9288736C6916Q50228192-081A8D47-DC4E-43F0-BDF4-660618F3F79F
P2860
The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1997
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The calcimimetic compound NPS ...... growth via a calcium receptor.
@en
The calcimimetic compound NPS ...... growth via a calcium receptor.
@nl
type
label
The calcimimetic compound NPS ...... growth via a calcium receptor.
@en
The calcimimetic compound NPS ...... growth via a calcium receptor.
@nl
prefLabel
The calcimimetic compound NPS ...... growth via a calcium receptor.
@en
The calcimimetic compound NPS ...... growth via a calcium receptor.
@nl
P2093
P2860
P356
P1476
The calcimimetic compound NPS ...... growth via a calcium receptor.
@en
P2093
J Sakiyama
N Kobayashi
P2860
P304
P356
10.1172/JCI119851
P407
P577
1997-12-01T00:00:00Z